Keywords: OS، بقا کلی; AUA, American Urological Association; NCCN, National Comprehensive Cancer Network; OS, overall survival; RCC, renal cell carcinomaCarcinoma; Renal cell; Neoplasm metastasis
مقالات ISI OS، بقا کلی (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: OS، بقا کلی; kidney neoplasms; kidney failure; chronic; proteinuria; glomerular filtration rate; mortalityCKD, chronic kidney disease; CKD-M, CKD due to medical causes; eGFR, estimated GFR; GFR, glomerular filtration rate; OS, overall survival; PN, partial nephrectomy
Keywords: OS، بقا کلی; urinary bladder neoplasms; neoadjuvant therapy; cystectomy; time factorsGC, gemcitabine and cisplatin; MIBC, muscle invasive bladder cancer; MVAC, methotrexate, vinblastine, doxorubicin and cisplatin; NAC, neoadjuvant chemotherapy; OS, overall survival; R
Keywords: OS، بقا کلی; testicular neoplasms; teratoma; cell transformation, neoplastic; neoplasms, germ cell and embryonal; drug therapyCSI, clinical stage I; GCT, germ cell tumor; OS, overall survival; PNET, primitive neuroectodermal tumor; RPLND, retroperitoneal lymph node di
Keywords: OS، بقا کلی; HCC, hepatocellular carcinoma; OS, overall survival; C-P, Child-Pugh; ALBI, albumin-bilirubin; BCLC, Barcelona Clinic Liver Cancer; AFP, α-fetoproteinHepatocellular carcinoma; Barcelona Clinic Liver Cancer; Overall survival; Albumin-bilirubin score; Curat
Keywords: OS، بقا کلی; ACC, adrenocortical carcinoma; ENSAT, European Network for Staging of Adrenal Tumors; HR, hazard ratio; LA, laparoscopic adrenalectomy; LND, lymph node dissection; NCDB, National Cancer Data Base; OA, open adrenalectomy; OS, overall survival
Keywords: OS، بقا کلی; CLM, colorectal liver metastases; OS, overall survival; PFS, progression-free survival; PVE, portal vein embolization
Keywords: OS، بقا کلی; CTC, circulating tumor cells; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; NACT, neoadjuvant chemotherapy; OS, overall survival; PR, progesterone; RFS, relapse-free survival; TNM, Tumor Node Metastasis
Keywords: OS، بقا کلی; DMFS, distant metastasis-free survival; FBS, fetal bovine serum; HIPAA, Health Insurance Portability and Accountability Act; IRB, Institutional review board; OS, overall survival; PRL, prolactin; PRLR, prolactin receptor; RFS, relapse-free survival; TMA,
Keywords: OS، بقا کلی; Age; Clinical feature; Outcome; Skull base chordomaCI, Confidence interval; K-M, Kaplan-Meier; KPS, Karnofsky Performance Status; MR, Magnetic resonance; OC, Occipitocervical; OS, Overall survival; PFS, Progression-free survival; REN, Signal intensity rat
Keywords: OS، بقا کلی; CRLM, colorectal cancer liver metastases; CRS, Clinical Risk Scores; Dx, diagnosis; HR, hazard ratio; OS, overall survival; Rf, initial referral; RFS, recurrence-free survival; Rx, resection
Keywords: OS، بقا کلی; FVPTC, follicular variant of papillary carcinoma; NCDB, National Cancer Data Base; OS, overall survival; p-PTC, pediatric papillary thyroid cancer; PT, partial thyroidectomy; TT, total thyroidectomyPediatric; Papillary thyroid cancer; Thyroidectomy
Keywords: OS، بقا کلی; bPFS, biochemical progression free survival; CI, confidence interval; ECOG PS, Eastern cooperative group performance status; EPR, electronic patient record; mCRPC, metastatic castration resistant prostate cancer; OS, overall survival; PM, Princess Margare
Keywords: OS، بقا کلی; urinary bladder; carcinoma; robotics; nephrectomy; mortalityCIS, carcinoma in situ; CSS, cancer specific survival; GFR, glomerular filtration rate; LVI, lymphovascular invasion; MFS, metastasis-free survival; OS, overall survival; RFS, recurrence-free sur
Keywords: OS، بقا کلی; 95% CI, 95% confidence interval; AUC, areas under the curve; EFS, event free survival; HR, hazard risk; LMR, lymphocyte-to-monocyte ratio; NLR, neutrophil-to-lymphocyte ratio; OS, overall survival; PLR, platelet-to-lymphocyte ratio; ROC, receiver operatin
Keywords: OS، بقا کلی; NLR, neutrophil-to-lymphocyte ratio; OS, overall survival; DFS, disease-free survival; RFS, recurrence-free survival; CSS, cancer specific survival; HR, hazard ratio; CI, confidence intervalBreast cancer; Inflammation; NLR; Prognosis
Keywords: OS، بقا کلی; DC-CIK, dendritic cells co-cultured with cytokine-induced killer cells; NSCLC, non-small-cell lung cancer; RCT, randomized controlled trial; PFS, progression-free survival; OS, overall survival; ORR, objective response rates; DCR, disease control rate; HR
Keywords: OS، بقا کلی; CDA, cytidine deaminase; OS, overall survival; ORR, overall response rate; HR, hazard ratio; OR, odds ratio; CI, confidence intervals; NSCLC, non-small cell lung cancer; NOS, Newcastle–Ottawa scale; HWE, Hardy–Winberg equilibriumCytidine deaminase; Single
Keywords: OS، بقا کلی; prostatic neoplasms; testosterone; antiandrogens; mortality; prognosisADT, androgen deprivation therapy; BMI, body mass index; CAB, combined androgen blockade; LHRH, luteinizing hormone-releasing hormone; OS, overall survival; PFS, progression-free surviv
Keywords: OS، بقا کلی; HGG, high-grade glioma; BVZ, bevacizumab; CPT11, irinotecan; FSRT, fractionated stereotactic radiotherapy; RANO, revised Assessment in Neuro-Oncology; MRI, magnetic resonance imaging; OS, overall survival; PFS, progression-free survival; TMZ, temozolomide
Keywords: OS، بقا کلی; ccRCC, Clear cell renal cell carcinoma; Pfn1, Profilin 1; OS, Overall survival; DFS, Disease-free survivalRenal cell carcinoma; Prognosis; Personalized medicine; Tumor markers; Profilin; Pfn1; Metastasis
Keywords: OS، بقا کلی; 10; 10.4BS, bone sarcoma; DFI, disease-free interval; DFS, disease-free survival; OS, overall survival; STS, soft tissue sarcoma; VATS, video-assisted thoracoscopic surgery
Keywords: OS، بقا کلی; AJCC, American Joint Committee on Cancer; HR, hazard ratio; OS, overall survival
Keywords: OS، بقا کلی; Astrocytoma; IDH1; Outcomes; SurgeryAII, WHO grade II astrocytomas; ECOG, Eastern Cooperative Oncology Group; IDH1, Isocitrate dehydrogenase 1; MRI, Magnetic resonance imaging; OS, Overall survival; PFS, Progression-free survival; WHO, World Health Organi
Keywords: OS، بقا کلی; HCC, hepatocellular carcinoma; LT, liver transplantation; CK19, cytokeratin protein 19; HR, hazard Ratio; EpCAM, epithelial cell adhesion molecule; OS, overall survival; miVI, microvascular invasion; TGFb, transforming growth factor-beta; CT, computed tom
Keywords: OS، بقا کلی; DFS, disease-free survival; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HR, hazard ratio; LR, liver resection; LT, liver transplantation; MELD, Model for End-Stage Liver Disease; OS, overall survival
Keywords: OS، بقا کلی; DSS, disease-specific survival; GI, gastrointestinal; HR, hazard ratio; NET, neuroendocrine tumor; OS, overall survival; S-LAR, long-acting somatostatin analogue
Keywords: OS، بقا کلی; CEA, carcinoembryonic antigen; ChT, chemotherapy; ES, extensive stage; HR, hazard ratio; KPS, Karnofsky performance status; LDH, lactate dehydrogenase; LS, limited stage; MST, median survival time; NSE, neuron-specific enolase; OS, overall survival; SCLC,
Keywords: OS، بقا کلی; EBL, estimated blood loss; GAC, gastric adenocarcinoma; HR, hazard ratio; OS, overall survival; RFS, recurrence-free survival
Keywords: OS، بقا کلی; ADAM8, a disintegrin and metalloprotease 8; GC, gastric cancer; OS, overall survival
Keywords: OS، بقا کلی; CIMP, CpG island methylator phenotype; GSEA, gene set enrichment analysis; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; miRNA, microRNA; NSCLC, non-small cell lung carcinoma; OS, overall survival; TCGA, the Cancer Genome Atlas
Keywords: OS، بقا کلی; SCLC, small-cell lung carcinomas; NSCLC, non-small cell lung carcinomas; MM, malignant mesothelioma; AdenoCA, adenocarcinomas; SQCLC, squamous cell lung cancers; LCAC, large cell anaplastic carcinomas; OS, overall survival; PFS, progression-free survival;
Keywords: OS، بقا کلی; EC, endometrial cancer; OS, overall survival; MMC, Montefiore Medical CenterMetformin; Endometrial cancer; Non-endometrioid; Adjuvant therapy; Retrospective cohort study
Keywords: OS، بقا کلی; lymph node excision; penile neoplasms; salvage therapyCT, computerized tomography; DSS, disease specific survival; ILND, inguinal lymph node dissection; OS, overall survival; PET, positron emission tomography
Keywords: OS، بقا کلی; DVT, deep venous thrombosis; ESA, erythropoietin stimulating agents; EVTE, early venous thromboembolic events; LVTE, late venous thromboembolic event; NSCLC, non-small cell lung cancer; OS, overall survival; PS, performance status; PVTE, prior venous thro
Keywords: OS، بقا کلی; urinary bladder; carcinoma; small cell; outcome and process assessment (health care); mortalityBPT, bladder preservation therapy; CCI, Charlson-Deyo comorbidity index; MMT, multimodal therapy; OS, overall survival; RC, radical nephrectomy; TURBT, transure
Keywords: OS، بقا کلی; DFS, disease-free survival; LN, lymph node; NSCLC, non-small cell lung cancer; OS, overall survival
Keywords: OS، بقا کلی; Gastric adenocarcinoma; Tumor-related factors; Overall survival; Disease-free survival; Lymph node metastasis ratioCI, confidence interval; GC, gastric cancer; DFS, disease-free survival; IL, interleukin; N, node; NR, node ratio; OS, overall survival; SD,
Keywords: OS، بقا کلی; DSS, disease-specific survival; HR, hazard ratio; OS, overall survival
Keywords: OS، بقا کلی; 5-FU, 5-fluorouracil; CRC, colorectal cancer; TS, thymidylate synthase; TSER, thymidylate synthase enhancer region; MTHFR, methylenetetrahydrofolate reductase; RFC1, reduced folate carrier 1; OS, overall survival; RFS, relapse-free survival; HR, hazard ra
Keywords: OS، بقا کلی; cDNA, complementary DNA; CK, cytokeratin; EGFR-TKI, epidermal growth factor receptor tyrosine kinase inhibitor; IHC, immunohistochemistry; NSCLC, non-small cell lung cancer; OS, overall survival; PCR, polymerase chain reaction; RFS, relapse-free survival;
Keywords: OS، بقا کلی; 10; 10.2; 10.4CT, computed tomography; FDG, fluorescence deoxyglucose; GGO, ground glass opacity; HU, Haunsfield unit; LC, lepidic component; LI, lymphatic invasion; OS, overall survival; PET, positron emission tomography; RFS, recurrence-free survival; S
Keywords: OS، بقا کلی; kidney; carcinoma; renal cell; sunitinib; drug-related side effects and adverse reactions; drug administration scheduleAE, adverse event; AS, alternative schedule; LDH, lactate dehydrogenase; mRCC, metastatic renal cell cancer; OS, overall survival; PFS,
Keywords: OS، بقا کلی; ALT, alternative lengthening of telomeres; FISH, fluorescence in situ hybridization; GI, gastrointestinal; HR, hazard ratio; NET, neuroendocrine tumor; NELM, neuroendocrine liver metastases; OS, overall survival; PanNET, pancreatic neuroendocrine tumor; T
Keywords: OS، بقا کلی; FIGO, International Federation of Gynecology and Obstetrics; OS, overall survival; RFS, relapse-free survival; VEGF, vascular endothelial growth factor; EGFR, epidermal growth factor receptor; CCNE1, cyclin E1; ERCC1, excision repair cross-complementation
Keywords: OS، بقا کلی; PDAC, pancreatic ductal adenocarcinoma; OS, overall survival; AUC, area under the curve; ROC, receiver operating characteristics; HR, hazard ratio; CI, confidence interval; AJCC, American Joint Committee on Cancer; PTH, parathyroid hormone; PTHrP, parathy
Keywords: OS، بقا کلی; HCC, hepatocellular carcinoma; FLC, fibrolamellar carcinoma; HR, hazard ratio; NCI, National Cancer Institute; OS, overall survival
Keywords: OS، بقا کلی; GIST, gastrointestinal stromal tumor; HPF, high-powered field; HR, hazard ratio; IQR, interquartile range; OS, overall survival; RFS, recurrence-free survival; TKI, tyrosine kinase inhibitor
Keywords: OS، بقا کلی; CS, cytoreductive surgery; HIPEC, hyperthermic intraperitoneal chemotherapy; MMC, mitomycin C; OS, overall survival; PMP, pseudomyxoma peritonei; PSD, peritoneal surface (malignant) disease
Keywords: OS، بقا کلی; kidney; carcinoma, renal cell; neoplasm metastasis; nephrectomy; mortalityCT, computerized tomography; IFN/IL-2, interferon/interleukin-2; LN, lymph node; MRI, magnetic resonance imaging; OS, overall survival; RCC, renal cell carcinoma; RN, radical nephre